Evolus, Inc.

EOLS Healthcare Drug Manufacturers Specialty & Generic

Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

7.10 0.47 −6.21%
Market cap
$500.0M
P/E
0.0×
Fwd P/E
−13.4×
Dividend yield
—
F-score
3/9
Altman Z
−1.87
Beneish M
−2.59
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Total current assets
142.92 151.34 112.42 100.80 178.80 127.61 152.20 94.34 72.82 0.21
Total non-current assets
82.95 81.23 76.58 77.18 78.68 81.46 88.25 77.51 79.41 77.28
Total Assets
225.87 232.57 189.00 177.98 257.48 209.07 240.44 171.84 152.23 77.50
Total current liabilities
75.31 62.96 48.29 46.51 57.66 180.25 24.44 5.28 212.75 63.31
Total non-current liabilities
173.67 164.09 161.40 112.98 117.94 101.78 136.55 82.18 15.03 21.29
Total liabilities
248.97 227.05 209.69 159.48 175.61 282.03 160.99 87.46 227.78 84.60
Common Equity (Total)
(23.11) 5.52 (20.69) 18.50 81.88 (72.96) 79.46 84.38 (75.54) (7.11)
Shareholders Equity (Total)
(23.11) 5.52 (20.69) 18.50 81.88 (72.96) 79.46 84.38 (75.54) (7.11)
Total Debt
146.10 121.51 120.36 71.88 71.22 114.89 74.71 16.90 72.64 59.76

Show all line items

In millions of $ except per-share values · columns are period end dates